(Q54652584)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808301%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808301%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808301%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Alessandro Gozzetti

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808301%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Michela Rondoni

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808301%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Monica Bocchia

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808301%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Marzia Defina

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808301%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Micaela Ippoliti

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808301%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Rosaria Crupi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808301%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Francesco Lauria

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808301%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

language of work or name

English

0 references

publication date

31 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808301%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

13 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808301%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808301%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808301%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

600-603

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808301%20AND%20SRC:MED&resulttype=core&format=json

Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial

13 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.141

Chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.141

Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.141

Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.141

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.141

Imatinib and beyond--exploring the full potential of targeted therapy for CML.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.141

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.141

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.141

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.141

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.141

Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.141

Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.141

How I monitor residual disease in chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.141

Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.141

Allogeneic stem cell transplants in chronic myeloid leukemia

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20808301

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2010.141

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20808301%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference